European Union, the 27-nation pact of the European countries, had been in advanced-stage talks to purchase potential pandemic vaccine from the US drugmakers Moderna, Johnson & Johnson, French pharmaceutical Sanofi and Germany’s biotech firms BioNtech and CureVac, at least two sources from the Brussels directly briefed over the issue had unveiled on Saturday on condition of anonymity as the sources were not authorized to speak over the matter on public.
In point of fact, latest move from the EU to secure a fluent flow of vaccines came against the backdrop of a deal reached on June by four of the EU states to purchase as many as 400 million doses of AstraZeneca vaccines, which the EU member states had pledged to make available to all of the 27 EU member nations.
Race for pandemic vaccine heats up after early US moves to secure promised vaccines and treatments
Apart from that, the sources had also added that the EU Commission had affirmed its ongoing talks with potential vaccine developers to EU Health Ministers at a meet in Berlin later last week, while confirming the EU move further, a spokesman for the EU Commission was quoted saying on Friday “We are in talk with several companies on possible COVID-19 vaccines.
” On top of that, sources were also quoted saying to a press agency on Saturday that the European Union had been planning to secure as many as 300 million doses of pandemic vaccine developed by the French pharmaceutical company Sanofi in cooperation with the UK-based drugmaker GlaxoSmithKline Plc., while a spokesperson for Sanofi said on Saturady, “The company has been in advanced talks with the EU for the delivery of 300 million doses.
” Concomitantly, the sources had also told that the ongoing discussions over potential pandemic vaccines were led by the four EU-member states which had carried out a deal with AstraZeneca for 400 million doses of vaccine last month such as Germany, France, Italy and Netherlands.